Nexstim Abps nya aktier har registrerats i handelsregistret
Företagsmeddelande, Helsingfors, 8.11.2023 kl. 11.00 (EET)
Nexstim Abps nya aktier har registrerats i handelsregistret
Nexstim Abp (NXTMH:HEX) (”Nexstim” eller ”bolaget”) meddelade den 3 november 2023 att under perioden från den 1 april till den 2 oktober 2023 har sammanlagt 1 000 nya aktier i Nexstim Abp tecknats baserade på bolagets optionsrätter 2020A.
Dessa aktier som tecknats med optionsrätter registrerades i handelsregistret den 8 november 2023. De nya aktierna ger ägarna fullständiga rättigheter som aktieägare i bolaget från och med registreringsdagen. Efter registrering i handelsregistret är det totala antalet aktier i Nexstim Abp 6 765 562.
Aktierna upptas för handel på Nasdaq Helsinki Oys First North Growth Market Finland -marknadsplats tillsammans med befintliga aktier från 9 november 2023.
Villkoren för aktieoptionsprogrammen med ytterligare information finns tillgängliga på bolagets hemsida https://www.nexstim.com/investors/.
För mer information gå in på bolagets webbplats på www.nexstim.com eller kontakta:
Leena Niemistö, styrelseordförande
+358 9 2727 170
leena.niemisto@nexstim.com
Bolagets Certified Advisor är Erik Penser Bank.
Om Nexstim Abp
Nexstim är ett finländskt tillväxtorienterat medicinteknikbolag som verkar på den globala marknaden. Vår mission är att möjliggöra individualiserad och effektiv diagnostik och behandling av svåra sjukdomar i hjärnan.
Nexstim har tagit fram en banbrytande teknik för icke-invasiv hjärnstimulering som bygger på transkraniell magnetstimulering (TMS) i kombination med 3D-navigering. Den unika tekniken möjliggör exakt och individuellt anpassad stimulering av det rätta området i hjärnan.
Affärsområdet diagnostik arbetar med kommersialisering av Nexstims NBS-system för navigerad hjärnstimulering (Navigated Brain Stimulation). NBS System 5 är det enda FDA-godkända och CE-märkta TMS-systemet för preoperativ kartläggning av hjärnbarken för motorik och tal.
Affärsområdet terapi marknadsför och säljer Nexstims NBS System 6, som fått godkännande från FDA för marknadsföring och försäljning i USA för behandling av egentlig depression. NBS 6 -systemet har i Europa fått CE-märkning för behandling av egentlig depression och kronisk neuropatisk smärta.
Nexstims aktier är noterade på Nasdaq First North Growth Market Finland.
Mer information finns på www.nexstim.com
Bilaga
För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.För att se det här innehållet från ml-eu.globenewswire.com måste du ge ditt medgivande sidans topp.
Om
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Följ GlobeNewswire by notified
Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.
Senaste pressmeddelandena från GlobeNewswire by notified
Nykredit Realkredit A/S – New final terms for Euro Medium Term Note Programme5.12.2023 08:32:38 CET | Press release
To Nasdaq Copenhagen Nykredit Realkredit A/S – New final terms for Euro Medium Term Note Programme Nykredit Realkredit A/S publishes final terms for an issue of SEK 500,000,000 Senior Non-Preferred Floating Rate Notes due 2027, which are issued pursuant to Nykredit Realkredit A/S's and Nykredit Bank A/S’s €15,000,000,000 Euro Medium Term Note Programme dated 12 May 2023. The final terms dated 1 December 2023 and the EMTN Programme dated 12 May 2023 are available for download on Nykredit's website at nykredit.com/ir. Enquiries may be addressed to Nykredit Realkredit A/S, Group Treasury, Nicolaj Legind Jensen, Head of Group Treasury, tel +45 44 55 11 10, or Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21. Attachment New_final_terms_for_Euro_Medium_Term_Note_Programme_Nykredit_Realkredit_A_S_2023-12-05_EN
Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities5.12.2023 08:30:00 CET | Press release
SIENA, Italy, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Philogen S.p.A. (BIT:PHIL) is pleased to announce that its new GMP facility located in Rosia Siena, is now GMP certified. The certification was granted by the GMP MED office of the Agenzia Italiana del Farmaco (AIFA) following an inspection occurred in July 2023. AIFA confirmed that Philogen new facility complies with the requirements and guidelines of Good Manufacturing Practice outlined in the Directive 2003/94/EC issued by the European Parliament. In the European Union, national competent authorities - AIFA in Italy - are responsible for inspecting manufacturing sites based within their own territories. Sites located in one European Member State also benefit from mutual recognition agreements (MRAs) that the European Commission has signed with the authorities of the United States, Switzerland, Canada, Israel, Australia, Japan and New Zealand concerning the conformity assessment of medicinal products. Philogen plant in Rosia was designe
Equinor ASA: Share buy-back5.12.2023 08:00:00 CET | Press release
Please see below information about transactions made under the fourth tranche of the 2023 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR). Date on which the fourth tranche of the 2023 programme was announced: 27 October 2023. The duration of the fourth tranche of the 2023 programme: 30 October 2023 to no later than 29 January 2024. From 27 November to 1 December 2023, Equinor ASA has purchased a total of 1,478,000 own shares at the Oslo Stock Exchange at an average price of NOK 347.8907 per share. Aggregated overview of transactions per day: DateAggregated volume (number of shares)Weighted average share price (NOK)Total transaction value (NOK)27 November298,000351.8852104,861,789.6028 November290,000351.1603101,836,487.0029 November302,000345.0671104,210,264.2030 November296,000348.2593103,084,752.801 December292,000343.1135100,189,142.00Previously disclosed buy-backs under the fourth tranche of the 2023 programme 5,609,000360.82142,023,847,117.50Total buy-backs under fo
AS Tallink Grupp Statistics for November 20235.12.2023 08:00:00 CET | Press release
In November 2023 AS Tallink Grupp transported 376,997 passengers, which is a 0.4% decrease compared to November 2022. The number of cargo units decreased by 20.8% to 26,547 units and the number of passenger vehicles decreased by 4.6% to 50,244 units in the same comparison. AS Tallink Grupp passenger, cargo unit and passenger vehicles numbers for November 2023 were the following: November 2023November 2022ChangePassengers376,997378,540-0.4%Finland-Sweden116,913131,606-11.2%Estonia-Finland225,068207,0718.7%Estonia-Sweden35,01639,863-12.2%Cargo Units26,54733,502-20.8%Finland-Sweden3,4184,066-15.9%Estonia-Finland19,03624,999-23.9%Estonia-Sweden4,0934,437-7.8%Passenger Vehicles50,24452,688-4.6%Finland-Sweden2,8403,804-25.3%Estonia-Finland46,22947,555-2.8%Estonia-Sweden1,1751,329-11.6% FINLAND–SWEDEN In November 2023, the Finland-Sweden results reflect the operation of the two cruise ferries on the Helsinki-Stockholm and one cruise ferry on the Turku-Kapellskär route. The cruise ferry Silja
Progress on share buyback programme5.12.2023 08:00:00 CET | Press release
Progress on share buyback programme ING announced today that, as part of our €2.5 billion share buyback programme announced on 2 November 2023, the company repurchased 22,777,914 shares during the week of 27 November 2023 up to and including 1 December 2023. The shares were repurchased at an average price of €12.78 for a total amount of €291,049,616.02. For detailed information on the daily repurchased shares, individual share purchase transactions and weekly reports, see the ING website at www.ing.com/investorrelations. In line with the purpose of the programme to reduce the share capital of ING, the total number of shares repurchased under this programme to date is 93,562,112 ordinary shares at an average price of €12.53 for a total consideration of €1,172,310,567.38. To date approximately 46.89% of the maximum total value of the share buyback programme has been completed. Note for editors For further information on ING, please visit www.ing.com. Frequent news updates can be found in